To identify factors that affect the therapeutic response of intravitreal bevacizumab in diabetic macular edema (DMO) and explore the correlation between the functional and anatomical outcomes observed.
Methods:
A retrospective, noncomparative, consecutive case series design was used. Baseline imaging data and clinical records of 65 eyes with DMO, secondary to type II diabetes mellitus, which received intravitreal bevacizumab for the first time in 2016, were analyzed. The central macular thickness (CMT), macular volume, and best-corrected visual acuity (BCVA), following the initial 3 injection loading phase were recorded. Outcomes were compared to multiple variables including glycemic control, diabetic retinopathy grade, DMO subtype on optical coherence tomography, and use of past macular laser therapy.
Results:
The participants' age ranged from 46 to 84 of which 63% were men and 37% were women. The mean baseline CMT was 443.21 μm. A mean reduction of 11.23% (P < 0.0005) in CMT was observed following the loading phase. Women exhibited a greater reduction in CMT (P = 0.032). Participants with diffuse retinal thickening (DRT) and with cystoid macular edema (CMO) showed a net reduction in CMT of 17.39% (P = 0.047) and 8.24% (P = 0.04) respectively. Eyes with proliferative diabetic retinopathy demonstrated a mean gain in CMT of 16.86% (P = 0.001).
Conclusions:
Female patients and DRT demonstrated a positive anatomical response. Patients with CMO and proliferative diabetic retinopathy displayed a negative therapeutic response. Such observations may be considered in clinical decision-making when opting for anti-vascular endothelial growth factor (VEGF) therapy for DMO.
Get full access to this article
View all access options for this article.
References
1.
Van DierenS., BeulensJWJ, Van Der SchouwY.T., GrobbeeD.E., and NealB.The global burden of diabetes and its complications: an emerging pandemic. Eur. J. Cardiovasc. Prev. Rehabil. 17:3–8, 2010.
2.
GuariguataL., WhitingD.R., HambletonI., BeagleyJ., LinnenkampU., and ShawJ.E.Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 103:137–149, 2014.
YauJWY, RogersS.L., KawasakiR., et al.Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 35:556–564, 2012.
5.
DasA., McGuireP.G., and RangasamyS.Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 122:1375–1394, 2015.
6.
ZhangX., ZengH., BaoS., WangN., and GilliesM.C.Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 4:27, 2014.
7.
BashshurZ.F., BazarbachiA., SchakalA., HaddadZ.A., El HaibiC.P., and NoureddinB.N.Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am. J. Ophthalmol. 142:1–9, 2006.
8.
HaritoglouC., KookD., NeubauerA., et al.Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 26:999–1005, 2006.
9.
WellsJ a, GlassmanA.R., AyalaA.R., et al.Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N. Engl. J. Med. 372:1193–1203, 2015.
10.
JoshiL., BarA., Tomkins-NetzerO., et al.Intravitreal bevacizumab injections for diabetic macular edema—predictors of response: a retrospective study. Clin. Ophthalmol. 10:2093–2098, 2016.
11.
Warid Al-LaftahF.A., ElshafieM., AlhashimiM., PaiA., and FarouqM.Pretreatment clinical variables associated with the response to intravitreal bevacizumab (Avastin) injection in patients with persistent diabetic macular edema. Saudi. J. Ophthalmol. 24:133–138, 2010.
12.
AielloL.P., BeckR.W., BresslerN.M., et al.Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 118:e5–14, 2011.
13.
SomanM., GanekalS., NairU., and NairKGR.Effect of panretinal photocoagulation on macular morphology and thickness in eyes with proliferative diabetic retinopathy without clinically significant macular edema. Clin. Ophthalmol. 6:2013–2017, 2012.
14.
Centers for Disease Control and Prevention (CDC). Vital signs: awareness and treatment of uncontrolled hypertension among adults—United States, 2003–2010. MMWR Morb. Mortal. Wkly. Rep. 61:703–709, 2012.
15.
KimB.Y., SmithS.D., and KaiserP.K.Optical coherence tomographic patterns of diabetic macular edema. Am. J. Ophthalmol. 142:405–412, 2006.
16.
CampbellR.J., CouplandS.G., BuhrmannR.R., KertesP.J.Optimal optical coherence tomography–based measures in the diagnosis of clinically significant macular edema. Arch. Ophthalmol. 125:619, 2007.
BezzinaA.OCT image demonstrating sub-retinal fluid and diffuse retinal thickening. 2016.
19.
BezzinaA.OCT image demonstrating hyper-reflective loci in diabetic macular oedema. 2016.
20.
BolzM., Schmidt-ErfurthU., DeakG., MylonasG., KriechbaumK., and ScholdaC.Optical coherence tomographic hyperreflective foci. a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 116:914–920, 2009.
21.
UjiA., MurakamiT., NishijimaK., et al.Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am. J. Ophthalmol. 153:710–717, 2012.
22.
BezzinaA.OCT demonstrating DMO resolution following the IVB loading phase. 2016.
23.
CohenM.H., GootenbergJ., KeeganP., and PazdurR.FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 12:356–361. 2007.
24.
SandlerA., GrayR., PerryM.C., et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355:2542–2550, 2006.
25.
MillerK., WangM., GralowJ., et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357:2666–2676, 2007.
26.
ArevaloJ.F., LasaveA.F., WuL., et al.Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group. Br. J. Ophthalmol. 100:1605–1610, 2016.
27.
GrisantiS., and ZiemssenF.Bevacizumab: off-label use in ophthalmology. Indian J. Ophthalmol. 55:417–420, 2007.
28.
WakeleeH.A., DahlbergS.E., BrahmerJ.R., et al.Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung. Cancer. 76:410–415, 2012.
29.
BrahmerJ.R., DahlbergS.E., GrayR.J., et al.Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the eastern cooperative oncology group trial 4599. J. Thorac. Oncol. 6:103–108, 2011.
30.
SoheilianM., RamezaniA., YaseriM., MirdehghanS.A., ObudiA., and BijanzadehB.Initial macular thickness and response to treatment in diabetic macular edema. Retina. 31:1564–1573, 2011.
31.
MushtaqB., CrosbyN.J., DimopoulosA.T., et al.Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema. Clin. Ophthalmol. 8:807–812, 2014.
32.
RohM.I., KimJ.H., and KwonO.W.Features of optical coherence tomography are predictive of visual outcomes after intravitreal bevacizumab injection for diabetic macular edema. Ophthalmologica. 224:374–380, 2010.
33.
WuP.C., LaiC.H., ChenC.L., and KuoC.N.Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment. J. Ocul. Pharmacol. Ther. 28:59–64, 2012.
34.
KimM., LeeP., KimY., YuS-Y, and KwakH-W.Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema. Ophthalmologica. 226:138–144, 2011.
35.
BresslerS.B., QinH., BeckR.W., et al.Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch. Ophthalmol. (Chicago, Ill 1960). 130:1153–1161, 2012.
36.
AmbatiJ., Chalam KV, ChawlaD.K., et al.Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch. Ophthalmol. 115:1161–1166, 1997.
37.
WatanabeD., SuzumaK., SuzumaI., et al.Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 139:476–481, 2005.
